Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

<p>Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 100% of bezuclastinib treated patients achieved at least 50% improvement across all relevant biomarker measures, including serum tryptase, KIT D816V VAF, and mast cell burden; Placebo patients, after [&#8230;]</p>
<p>The post <a href="https://forextv.com/top-news/cogent-biosciences-announces-positive-initial-data-from-phase-2-summit-trial-evaluating-bezuclastinib-in-patients-with-nonadvanced-systemic-mastocytosis-nonadvsm/">Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>